Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient.
J Oncol Pharm Pract
; 26(8): 2031-2033, 2020 Dec.
Article
em En
| MEDLINE
| ID: mdl-32340536
ABSTRACT
INTRODUCTION:
Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. CASE REPORT In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC).Management andoutcome:
She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event.DISCUSSION:
Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Sulfonas
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Quinase do Linfoma Anaplásico
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article